Zinaxil 500

Zinaxil 500

-Cefuroxime axetil is an oral prodrug of the bactericidal cephalosporin           antibiotic,  Cefuroxime, which is active against a wide range of
 Gram-positive and Gram-negative organisms. 
-Cefuroxime is resistant to most beta-lactamases and consequently, is active
  against many Ampicillin-resistant strains and Amoxicillin-resistant strains. 
 The bactericidal action of Cefuroxime results from inhibition of cell-wall 
 synthesis by binding to essential target proteins. 
-Cefuroxime axetil is absorbed from the gastro-intestinal tract and is rapidly
 hydrolysed in the intestinal mucosa and blood to Cefuroxime. The
 absorption of Cefuroxime axetil is enhanced in the presence of  food . 
-Peak plasma level of Cefuroxime in plasma occur approximately 2 to 3 
 hours after oral administration .The plasma half life is about 1.2 hours . 
 Plasma levels of Cefuroxime is reduced by dialysis .
-Cefuroxime bound to plasma protein by 50% .
-Cefuroxime is widely distributed in the body. It crosses the placenta and
 has been detected in breast milk. 
- Cefuroxime is not metabolised and is excreted unchanged in the urine. 
 Small amounts of Cefuroxime are excreted in bile. 

* Each Film coated tablet  of   ZINAXIL® 500  contains:
    Cefuroxime 500 mg (as Cefuroxime axetil USP) .
* Each Film coated tablet  of   ZINAXIL® 250  contains:
    Cefuroxime 250 mg (as Cefuroxime axetil USP) 
* Each Film coated tablet  of   ZINAXIL® 125  contains:
    Cefuroxime 125 mg (as Cefuroxime axetil USP)
* Each 5ml of  ZINAXIL® 250 for oral suspension contains:
    Cefuroxime 250mg (as Cefuroxime axetil USP).
* Each 5ml of   ZINAXIL® 125for oral suspension contains:
    Cefuroxime 125mg (as Cefuroxime axetil USP) .

 ZINAXIL® is contraindicated in patients with known hypersensitivity  to the
 Cephalosporins antibiotics. 

-Probenecid competes for renal tubular secretion with ZINAXIL®  resulting in
  higher and more prolonged plasma concentrations of cefuroxime.  

- ZINAXIL® should be administered with caution during the early months of 
  pregnancy. 
-Cefuroxime is excreted in breast  milk, and consequently caution should be 
  exercised when  ZINAXIL® is administered to a nursing mother.

Generally mild and transient in nature: 
-As with other Cephalosporins, there have been rare reports of hypersensitivity
 reactions including skin rashes, urticaria, pruritis, drug fever and very rarely 
 anaphylaxis. 
-Gastrointestinal disturbances, including diarrhoea, nausea, and vomiting, have 
 occurred in some patients receiving  ZINAXIL®. Diarrhoea, although 
 uncommon, is more likely to be associated with higher doses.
-Headache has  been reported. 
-Eosinophilia and transient increases of hepatic enzyme levels have been noted
 during  ZINAXIL® therapy

-As with other antibiotics, prolonged use of  ZINAXIL® may result in the
 overgrowth of non-susceptible organisms 
 (eg., Candida, Enterococci, Clostridum difficile), which may require 
 interruption of treatment. 
-Pseudomembranous colitis has been reported with the use of broad-spectrum 
 antibiotics, therefore, it is important to consider its diagnosis in patients who
 develop diarrhoea during or after antibiotic use. 
-Special care is indicated in patients who have experienced an anaphylactic 
  reaction to penicillins.
- ZINAXIL® should be given with caution to patients receiving concurrent 
 treatment with potent diuretics because these diuretics are suspected of
 adversely affecting renal function. 
-False positive reactions may occur if using methods depending on copper 
reduction eg. Fehling’s, Benedict’s, solutions and   Clinitest.  There for 
  enzyme-based tests should be used.

-  ZINAXIL® 500 mg ,250 mg &125 mg  Tablets: 
  (Blister of 5 tablets, Pack  of two  blisters).
-  ZINAXIL®   for Oral suspension 250mg &125 mg : 
     ( Bottle of 60 ml after preparation) .

-Store the drug in a dry place at a temperature  below 30oC.
- ZINAXIL®  for  Oral suspension, once reconstituted, must be stored in a
 refrigerator and used within one weak .